[go: up one dir, main page]

MX2016006500A - Derivado de urea o sal farmacologicamente aceptable del mismo. - Google Patents

Derivado de urea o sal farmacologicamente aceptable del mismo.

Info

Publication number
MX2016006500A
MX2016006500A MX2016006500A MX2016006500A MX2016006500A MX 2016006500 A MX2016006500 A MX 2016006500A MX 2016006500 A MX2016006500 A MX 2016006500A MX 2016006500 A MX2016006500 A MX 2016006500A MX 2016006500 A MX2016006500 A MX 2016006500A
Authority
MX
Mexico
Prior art keywords
acceptable salt
pharmacologically acceptable
urea derivative
general formula
relates
Prior art date
Application number
MX2016006500A
Other languages
English (en)
Other versions
MX367193B (es
Inventor
Takahashi Hiroyasu
Saito Yoshifumi
Tsuda Kosuke
Shibasaki Mitsuhito
Ohata Kohei
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MX2016006500A publication Critical patent/MX2016006500A/es
Publication of MX367193B publication Critical patent/MX367193B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Un compuesto con efecto agonista sobre el receptor similar al de péptidos formilados 1 (FPRL1). La presente invención se refiere a un compuesto representado por la fórmula general (I) o una sal del mismo farmacológicamente aceptable (ver Fórmula) La presente invención también se refiere a una composición farmacéutica que contiene el compuesto representado por la fórmula general (I) o una sal del mismo farmacológicamente aceptable, y al uso farmacéutico del mismo.
MX2016006500A 2013-11-28 2014-11-27 Derivado de urea o sal farmacologicamente aceptable del mismo. MX367193B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013245502 2013-11-28
PCT/JP2014/005933 WO2015079692A1 (ja) 2013-11-28 2014-11-27 ウレア誘導体、またはその薬理学的に許容される塩

Publications (2)

Publication Number Publication Date
MX2016006500A true MX2016006500A (es) 2016-12-02
MX367193B MX367193B (es) 2019-08-08

Family

ID=53198654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006500A MX367193B (es) 2013-11-28 2014-11-27 Derivado de urea o sal farmacologicamente aceptable del mismo.

Country Status (35)

Country Link
US (6) US9822069B2 (es)
EP (2) EP3075726B1 (es)
JP (3) JP6453231B2 (es)
KR (1) KR102252270B1 (es)
CN (1) CN105814019B (es)
AU (2) AU2014355887B2 (es)
BR (1) BR112016011755B1 (es)
CA (1) CA2932010C (es)
CL (1) CL2016001283A1 (es)
CY (1) CY1120089T1 (es)
DK (1) DK3075726T3 (es)
EA (1) EA030474B1 (es)
ES (2) ES2659156T3 (es)
HR (1) HRP20180199T1 (es)
HU (1) HUE036497T2 (es)
IL (1) IL245823B (es)
LT (1) LT3075726T (es)
MA (1) MA39069B1 (es)
MX (1) MX367193B (es)
MY (1) MY179516A (es)
NO (1) NO3075726T3 (es)
NZ (2) NZ720508A (es)
PE (1) PE20161206A1 (es)
PH (1) PH12016500806B1 (es)
PL (1) PL3075726T3 (es)
PT (1) PT3075726T (es)
RS (1) RS57036B1 (es)
SA (1) SA516371205B1 (es)
SG (1) SG11201604296QA (es)
SI (1) SI3075726T1 (es)
SM (1) SMT201800061T1 (es)
TN (1) TN2016000210A1 (es)
TW (1) TWI649305B (es)
WO (1) WO2015079692A1 (es)
ZA (1) ZA201603624B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3075726T1 (en) * 2013-11-28 2018-05-31 Kyorin Pharmaceutical Co., Ltd. DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS
AR104751A1 (es) 2015-05-27 2017-08-09 Kyorin Seiyaku Kk Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico
WO2017100390A1 (en) * 2015-12-10 2017-06-15 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
TW201815762A (zh) 2016-09-21 2018-05-01 德商歌林達有限公司 經尿素及苯基取代之６員環狀胺或內醯胺
JP2020015664A (ja) * 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
US20210128699A1 (en) * 2017-01-13 2021-05-06 Tobishi Pharmaceutical Co., Ltd. Neutrophil activation regulator
EA201992704A1 (ru) * 2017-05-22 2020-03-19 Бристол-Маерс Сквибб Компани Новое применение агониста формил-пептидного рецептора 2/рецептора липоксина a4 (fpr2/alx) для лечения сердечной недостаточности
WO2018227067A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2018227061A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
ES2869129T3 (es) * 2017-06-09 2021-10-25 Bristol Myers Squibb Co Agonistas de piperidinona del receptor 2 de péptidos formilados
WO2018227065A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
HUE058044T2 (hu) * 2018-03-05 2022-06-28 Bristol Myers Squibb Co Fenilpirrolidinon-formil peptid 2 receptor agonisták
AR114383A1 (es) * 2018-03-09 2020-08-26 Gruenenthal Gmbh Piperidinas o piperidonas sustituidas con urea y fenilo
US20210395200A1 (en) 2018-11-16 2021-12-23 Bristol-Myers Squibb Company Synthetic processes for the production of 1-((3s,4r)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl)-3-phenylurea
KR102877973B1 (ko) * 2018-11-26 2025-10-30 브리스톨-마이어스 스큅 컴퍼니 포르밀 펩티드 2 수용체 효능제로서의 피롤리디논 유도체
EP3789378A1 (en) * 2019-09-06 2021-03-10 Grünenthal GmbH Piperidines or piperidones substituted with urea and heteroaryl
AR122912A1 (es) * 2020-07-09 2022-10-12 Bristol Myers Squibb Co Agonistas de oxopirrolidina fpr2
US20230303513A1 (en) * 2020-08-12 2023-09-28 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
EP4447681A2 (en) 2021-12-15 2024-10-23 Adama Agan Ltd. Compounds useful for the preparation of various agrochemicals and markers thereof
WO2025217248A1 (en) * 2024-04-11 2025-10-16 Corteva Agriscience Llc Formulations containing substituted 5-membered ring pesticides and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13001A (en) 1855-06-05 Method of composing- music
US5202344A (en) * 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
CN1894580A (zh) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
TWI434685B (zh) 2007-12-18 2014-04-21 Actelion Pharmaceuticals Ltd 胺基三唑衍生物
EP2336105B9 (en) * 2008-09-19 2014-09-17 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
US7881231B2 (en) 2009-02-13 2011-02-01 Microsoft Corporation Detection of home network configuration problems
KR20110117194A (ko) 2009-02-23 2011-10-26 에프. 호프만-라 로슈 아게 암 치료를 위한 신규한 오르토-아미노아미드
CN102803237B (zh) 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
PT2649068E (pt) 2010-12-07 2014-12-23 Actelion Pharmaceuticals Ltd Derivados de éter oxazolil-metílico como agonistas do receptor de alx
JP5923108B2 (ja) 2010-12-07 2016-05-24 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのヒドロキシル化アミノトリアゾール誘導体
US8580817B2 (en) 2011-02-11 2013-11-12 Allergan, Inc. 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
RS55582B1 (sr) 2011-05-13 2017-06-30 Array Biopharma Inc Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze
EP2731931A1 (en) 2011-07-11 2014-05-21 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
AU2012329098B2 (en) * 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
CA2870356A1 (en) 2012-04-16 2013-10-24 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
ES2708571T3 (es) 2013-07-16 2019-04-10 Allergan Inc Derivados de aminoácidos sustituidos con N-urea como moduladores del receptor de péptido formilado
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
SI3075726T1 (en) * 2013-11-28 2018-05-31 Kyorin Pharmaceutical Co., Ltd. DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS
KR102395827B1 (ko) 2013-12-03 2022-05-10 에프엠씨 코포레이션 제초제로서의 피롤리디논
WO2015175788A1 (en) 2014-05-15 2015-11-19 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US10336723B2 (en) 2015-01-23 2019-07-02 Gvk Biosciences Private Limited Inhibitors of TrkA kinase

Also Published As

Publication number Publication date
US20210107869A1 (en) 2021-04-15
US20180290974A1 (en) 2018-10-11
ES2659156T3 (es) 2018-03-14
IL245823B (en) 2019-09-26
PT3075726T (pt) 2018-02-16
AU2019203119B2 (en) 2020-11-12
HRP20180199T1 (hr) 2018-05-04
EA030474B1 (ru) 2018-08-31
NO3075726T3 (es) 2018-04-07
IL245823A0 (en) 2016-08-02
MA39069B1 (fr) 2018-11-30
TW201609636A (zh) 2016-03-16
CA2932010A1 (en) 2015-06-04
TWI649305B (zh) 2019-02-01
PL3075726T3 (pl) 2018-05-30
PH12016500806B1 (en) 2019-11-29
US20200010415A1 (en) 2020-01-09
CN105814019A (zh) 2016-07-27
CN105814019B (zh) 2019-12-06
DK3075726T3 (en) 2018-02-12
CL2016001283A1 (es) 2017-01-27
SMT201800061T1 (it) 2018-05-02
SG11201604296QA (en) 2016-07-28
CY1120089T1 (el) 2018-12-12
JPWO2015079692A1 (ja) 2017-03-16
JP6453231B2 (ja) 2019-01-16
US11261155B2 (en) 2022-03-01
EA201691119A1 (ru) 2016-11-30
AU2014355887A1 (en) 2016-06-16
PH12016500806A1 (en) 2016-06-13
CA2932010C (en) 2020-07-07
ZA201603624B (en) 2019-04-24
ES2752733T3 (es) 2020-04-06
EP3075726A4 (en) 2017-05-31
RS57036B1 (sr) 2018-05-31
TN2016000210A1 (en) 2017-10-06
SI3075726T1 (en) 2018-05-31
NZ752095A (en) 2022-07-01
LT3075726T (lt) 2018-03-26
MY179516A (en) 2020-11-09
US10252992B2 (en) 2019-04-09
KR20160090304A (ko) 2016-07-29
BR112016011755B1 (pt) 2023-05-02
MX367193B (es) 2019-08-08
BR112016011755A2 (pt) 2017-09-26
JP2019059772A (ja) 2019-04-18
EP3075726A1 (en) 2016-10-05
US10696630B2 (en) 2020-06-30
EP3305763A1 (en) 2018-04-11
EP3305763B1 (en) 2019-07-24
HUE036497T2 (hu) 2018-07-30
NZ720508A (en) 2019-03-29
KR102252270B1 (ko) 2021-05-13
AU2014355887B2 (en) 2019-02-07
US20190161445A1 (en) 2019-05-30
JP2021001181A (ja) 2021-01-07
PE20161206A1 (es) 2016-11-05
WO2015079692A1 (ja) 2015-06-04
MA39069A1 (fr) 2018-07-31
US20170066718A1 (en) 2017-03-09
EP3075726B1 (en) 2017-11-08
AU2019203119A1 (en) 2019-05-30
US10029983B2 (en) 2018-07-24
US9822069B2 (en) 2017-11-21
SA516371205B1 (ar) 2018-03-26
US10464891B2 (en) 2019-11-05
US20180044290A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
PH12016500806A1 (en) Urea derivative or pharmacologically acceptable salt thereof
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
EP3450449A3 (en) Peptide compositions
MX2018001517A (es) Derivados sustituidos de guanidina.
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
MX366983B (es) Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
PH12016502246A1 (en) Carboxamide derivatives
PH12016500461A1 (en) Polyethylene glycol-containing composition
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
PH12015501146A1 (en) Hydantoin derivative
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
GB201020397D0 (en) Compounds
NZ717192A (en) Anti-inflammatory tripeptides
EA201690908A1 (ru) Пиразолопиримидиновые соединения
MX2019007786A (es) Compuestos sustituidos de guanidina.
IN2013DE00880A (es)

Legal Events

Date Code Title Description
FG Grant or registration